Institut de Cancérologie de l’Ouest,
Bd J Monod,
44 805 Nantes,
France, Hôpital Saint-Antoine,
service d’oncologie médicale,
This review traces a new concept of treatment in metastatic colo-rectal cancer called “sustained angiogenesis inhibition beyond progression”. In clinical practice, a multiline strategy is commonly defined, using each active drug in sequential therapeutic schedules. The clinical benefit demonstration of maintaining anti-angiogenic therapy beyond progression while switching chemotherapy across multiple lines allows to validate a new therapeutic strategy in mCCR.